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Summary  
Background and Purpose: Cryptotanshinone (CTs) is a major active component of 
Salvia miltiorrhiza, which is often used as Chinese herbal medicine in cancer therapy. 
Here, we systematically assessed the anti-tumor effect of CTs on two melanoma cell 
lines with low/high metastatic capacity (B16/B16BL6). 
Experimental Approach: MTT and LDH assays were used to evaluate cell growth and 
cytotoxicity. We assessed the effect of CTs on cell apoptosis or proliferation by 
Annexin V, TUNEL or BrdU assay. Cell cycle distribution was detected by flow 
cytometry. The integrity of cell cycle checkpoints was determined by mutational 
analyses of B-RAF and N-RAS, and the expression of cell cycle associated proteins by 
western blotting. 
Key Results: Treatment with CTs had no obvious effect on cell apoptosis, but 
significantly inhibited cell proliferation. CTs induced the expression of p53, Chk1 and 
Chk2 in both B16 and B16BL6. Interestingly, CTs induced G1 arrest in B16BL6 cells, 
together with an increase in protein levels of p21. By contrast, in B16 cells, CTs 
induced the G2/M arrest through induction of Cdc25c. Regulation of Cyclin A1, Cyclin 
B1 and Cdk1/cdc2 expression level might contribute to the different cell cycle patterns 
in B16 and B16BL6 after CTs treatment. 
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Conclusions and Implications: CTs could have opposite effects on cell cycle events in 
melanoma cell lines with different metastatic capacity. This property might offer an 
opportunity to study the mechanisms underlying the different anti-tumor effects of CTs 
on B16 and B16BL6. 
Key words: cryptotanshinone, cell cycle-arrest, melanoma, B16, B16BL6 
 
Introduction 
Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are 
found predominantly in the skin [1]. The incidence of melanoma in many countries has 
risen by 3-8% per year since the mid 1960s [2, 3] and in western populations the 
number of cases has doubled in the past 20 years [1]. It is an extremely aggressive 
disease with high metastatic potential and a notoriously high resistance to cytotoxic 
agents. This is thought to be because melanocytes originate from highly motile cells that 
have enhanced survival properties [4]. Melanomagenesis is associated with defects in 
nucleotide excision repair of solar radiation-induced DNA damage, and cell cycle 
checkpoints that arrest growth after DNA damage and oncogene activation [5].  
 
The identification of new drugs from plants has a long and successful history [6]. Salvia 
miltiorrhiza (Danshen), a well-known traditional Chinese herbal medicine, is widely 
used in the clinical treatment of different diseases [7-10]. In the Dictionary of 
Traditional Chinese Medicine Prescription, Salvia miltiorrhiza came in fourth place 
among 1362 anti-cancer classic and empirical prescription by frequency analysis. 
Chemical constituents of this medicine have been investigated since 1934. Along with 
more than 20 phenolic acids, about 30 diterpene compounds have been isolated from 
Danshen, including the relatively abundant tanshinones, such as tanshinone I, 
tanshinone IIA, cryptotanshinone, dihydrotanshinone [8]. Cryptotanshinone (CTs), as a 
major active component, has been shown to possess pharmacological activities, such as 
anti-cholinesterase, anti-inflammatory, anti-oxidative, anti-bacterial, anti-tumor and 
anti-platelet aggregation properties [11-16]. Recent studies have also shown that CTs is 
a potential anticancer agent [17, 18]. However, the anti-cancer mechanisms of CTs 
remains to be elucidated. 
 
Tumorigenesis encompasses multiple processes involving the dysregulation of a number 
of molecular pathways, such as cell cycle proliferation and apoptosis. The strategy 
behind some forms of drug therapy is to either retard cell cycle progression or induce 
apoptosis. The aim of this study was to investigate the possible roles of CTs on 
melanoma cell lines with different metastatic capacity, including the high-metastatic 
potential melanoma cell line (B16BL6) and the low-metastatic potential melanoma cell 
line (B16). The use of pairs of cell lines, one with a very low and the other with a very 
high capacity to metastasize, offers an opportunity to dissect out the various processes 
involved.  
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Materials and methods 
Animals 
Female C57BL/6 mice (6-8 weeks old) were purchased from the Slac Animal Inc 
(Shanghai, China). Throughout the experiments, mice were maintained in plastic cages 
at 21±2 °C, on a 12 h light/dark cycle and with free access to food and water. Animal 
welfare and experimental procedures were performed strictly in accordance with the 
care and use of laboratory animals, and the related ethics regulations of our University. 
All possible efforts were made to minimize the animals’ suffering and to reduce the 
number of animals used.  
 
Cell lines and Culture condition 
These studies utilized C57BL/6 mice-derived melanoma cell lines, including B16 (low 
metastatic potential) and B16BL6 (high metastatic potential). The cells were cultured as 
a monolayer in DMEM (Gibco, Grand Island, NY, USA), containing 10% v/v Fetal 
Bovine Serum (Hyclone, Canada), penicillin (100 IU/ml), streptomycin (100 μg/ml) and 
3.7 mg/ml NaHCO3. All cells were grown in a humidified atmosphere, containing 5% 
CO2 at 37°C. 
 
Experimental metastasis model 
The suspension of B16 or B16BL6 cells (5×105 cells in 0.2 ml per mouse) were injected 
through the tail vein of a 6-8 week old female C57BL/6J mice, and allowed to locate to 
the lungs, where they extravasated into the lung parenchyma. All mice were sacrificed 
23 days after the injection of the tumor cells. The lungs were then removed, weighed 
and fixed. The metastastic foci on the surfaces of the lung were photographed and 
counted.  
 
MTT assay 
In this study, 100 mM stock solution of cryptotanshinone (Xi'an Helin Biological 
Engineering Co., Ltd. Xi'an, China, purity > 95%) was prepared in ethanol, then filtered 
by 0.2 μm membrane and diluted as indicated. The growth inhibition effect of 
cryptotanshinone on melanoma cells was carried out using the MTT assay. Briefly, 
exponentially growing cells, seeded in 96-well plates (5×103 cells/well), were incubated 
in the presence of different concentrations (0.1 to 100 µM) of cryptotanshinone for 
different periods of time. At the end of the incubation period 20 μl of a stock solution of 
5 mg/ml MTT (Amresco,USA) was added to each well, and plates were gently shaken 
4 
 
and incubated at 37℃. After a further 4 h incubation the cells were lysed with dimethyl 
sulfoxide and quantified at OD490 using an enzyme-linked immunosorbent assay reader.  
 
Cell morphological analysis 
Cells were seeded at a density of 1.5 × 105 cells/well in a 6-well plate and grown 
overnight. The next day, different concentrations of cryptotanshinone were added (final 
concentration of 0, 1, 10, 25 μM). After incubation for 24 h, images of the cell 
morphological changes were taken with an inverted microscope at a ×100 magnification 
by a Leica Qwin system (Leica, LEITZ WETZLAR, Germany). 
 
LDH assay 
Cytotoxicity was determined by measuring cell membrane damage through the release 
of lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell 
membrane damage or cell lysis. For this experiment, exponentially growing cells were 
seeded in 96-well plates (5×103 cells/well) and incubated for 24 h in complete medium. 
The cells were then incubated in the presence of varying concentrations of 
cryptotanshinone as indicated for 24 h. Culture supernatants were then collected from 
each well, and the LDH release assay was performed according to the manufacturer’s 
instructions. The LDH kit was purchased from the Nanjing Jiancheng Bioengineering 
Institute (Nanjing, China). 
 
Anexin V assay 
Cells, seeded in 6-well plates at a density of 2×105 cells/well in growth medium, were 
grown overnight at 37°C in a humidified incubator with 5% CO2. Cells were then 
treated with cryptotanshinone (0, 1, 10, 25 μM) for 24 h. Cell apoptosis was assessed by 
Annexin V-FITC staining using a flow cytometric apoptosis detection kit (Cat.No. 
556420, BD Biosciences Pharmingen, San Jose, CA). The stained cells with Annexin 
V-FITC and propidium iodide [7] were analyzed using a BD FACSCalibur™ flow 
cytometer and CellQuest analysis software (BD Biosciences, Mountain View, CA). 
 
TUNEL assay 
Cells (1.8×105 cells/well) were seeded in growth medium on Poly-L-Lysine (P4707, 
Sigma) coated cover glass slides in 6-well plates and grown overnight at 37°C, in a 
humidified incubator with 5% CO2. Cells were then treated with cryptotanshinone (0, 1, 
10, 25 μM) for 24 h. Then slides were washed with PBS and then fixed in 4% PFA. 
After rinsing in PBS, cells were examined for apoptosis by terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL) assay (Promega, Madison, WI) , 
performed according to the manufacturer’s instructions as previously described [19]. 
Cells were visualized and photographed using Leica TCS-SL confocal system (Leica 
Microsystems, Mannheim, Germany). At least 5 randomly chosen areas in every slide 
were used. The TUNEL labelling index was defined as the percentage of TUNEL 
positive cells against the total number of cells counted.  
 
BrdU assay 
Cells (1.8×105 cells/well) were seeded in growth medium on Poly-L-Lysine coated 
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cover glass slides in 6-well plates and grown overnight at 37°C in a humidified 
incubator, with 5% CO2. Cells were then treated with cryptotanshinone (0, 1, 10, 25 μM) 
for 24 h. After that, cells were incubated with BrdU (B5002, Sigma) at a final 
concentration of 10 μM for 30 minutes at 37℃. The slides were washed with cold PBS 
prior to fixing with 4% PFA for 10 minutes. Subsequently, slides were washed with PBS 
and incubated with 2N HCl for 25 minutes. After washing with PBS and incubating 
with blocking buffer (5% bovine serum albumin, 10% normal goat serum and 0.5% 
Tween 20 in PBS), the slides were incubated with mouse anti-BrdU antibody (1:100, 
Roche) at 37℃ for 2 h. The slides were then washed with PBS and incubated with 
FITC-labeled goat anti-mouse IgG (1:200, Sigma) for 1 hour at room temperature. After 
washing again, the slides were incubated with Topro-3 (1:300, Invitrogen) in PBS for 15 
minutes to counterstain the nuclei, and mounted on slides using 50% glycerol. Cells 
were visualized and photographed using Leica TCS-SL confocal system. At least 5 
randomly chosen areas in every slide were taken. The BrdU labelling index was defined 
as the percentage of BrdU positive cells against the total number of cells counted.  
 
Cell Cycle assay 
Cells were seeded in growth medium in 60-mm dishes at a density of 3×105 cells/dish 
and were grown overnight at 37°C, in a humidified incubator with 5% CO2. Cells were 
then treated with cryptotanshinone (0, 1, 10, 25 μM) for 6, 12, 24, 48 h. The population 
at each stage of the cell cycle was analyzed by flow cytometry. Briefly, cells were 
trypsinized, washed twice with PBS, and fixed in 70% ethanol over night at -20℃. 
Fixed cells were then washed with PBS, incubated with 0.5 ml PBS containing 100 
μg/ml RNase and stained with 40 μg/ml propidium iodide for 30 min at 37℃. The 
stained cells were analyzed using a BD FACSCalibur™ flow cytometer and CellQuest 
analysis software (BD Biosciences, Mountain View, CA). 
 
Mutational Analyses of B-RAF and N-RAS 
The N-RAS and B-RAF mutational status was determined from genomic DNA for the 
melanoma cell lines (B16 and B16BL6). Genomic DNA was isolated from cells, and the 
mutational status of N-RAS at exons 1 and 2, and B-RAF at exons 14 and 18 were 
determined as follows: PCR amplification utilized the following primers [20], then PCR 
products were purified from 1% agarose gels and DNA was sequenced using the 
forward PCR primers at GenScript Corporation (Nanjing, China) 
 
N-RAS at exon 1 forward: 5'-TTGCTGCTTTTCTACAGG-3',  
reverse: 5'-CCAAAGTGAGGATAAGGG-3'; 
N-RAS at exon 2 forward: 5'-CCTCCTCACTCTTTCATATTCC-3',  
reverse: 5'-CAGAAAATATCCCCAGTACC-3'; 
B-RAF at exon 14 forward: 5'-GGCAGGTCAATATAGTTAGC-3',  
reverse: 5'-CGTGTTATACATACCATGTCC-3'; 
B-RAF at exon 18 forward: 5'-CAAAATGCTTTCTCTAATAGG-3',  
reverse: 5'-TAAGCAGTCACTAGTTTAGG-3'. 
 
Western blotting assay 
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To detect the effects on cell cycle associated protein expression in B16 and B16BL6 cells, 
cells seeded in 6-well plates at a density of 3×105 cells/well in growth medium, were grown 
overnight at 37°C in a humidified incubator with 5% CO2. Cells in culture were then treated 
with different concentrations of cryptotanshinone or media only (control) for 24 h. After that, 
cells were washed by pre-cooled PBS and lysed in RIPA buffer (50 mM Tris-Cl pH7.4, 150 
mM NaCl, 1% NP-40, 0.1% SDS, 0.25% sodium deoxycholate) supplemented with 1 mM 
PMSF, 1 mM Na3VO4, 1 mM NaF, and 1:100 dilution of Protease Inhibitor Cocktail (Sigma, 
St. Louis, MO, USA). The supernatant containing the protein was collected and the 
concentration determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., 
Hercules, CA). Protein samples were resolved by SDS-PAGE and transferred to a 
polyvinylidene difluoride membrane (Millipore, Billerica, MA). p53, Chk1, Chk2, p21, 
Cyclin A1, Cyclin B1, Cdk1/Cdc2 and Cdc25C proteins were detected by immunoblot with 
anti-p53 (1:500, NCL-p53-CM5p, NovoCastra, Newcastle, U.K.) , anti-Chk1 (1:200, BS1053, 
Bioworld Technology, Bioworld, U.S.A.), anti-Chk2 (1:200, BS1391, Bioworld Technology, 
Bioworld, U.S.A.), anti-p21 (1:200, sc-6246, Santa Cruz Biotechnology, Santa Cruz, CA), 
anti-Cyclin A1 (1:200, BS1804, Bioworld Technology, Bioworld, U.S.A.), anti-Cyclin B1 
(1:200, sc-752, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Cdk1/Cdc2 (1:200, BS1820, 
Bioworld Technology, Bioworld, U.S.A.), anti-Cdc25C (1:200, sc-327, Santa Cruz 
Biotechnology, Santa Cruz, CA) polyclonal antibody and β-actin (1:15000; Sigma St Louis, 
MO, U.S.A.) or GAPDH (1:5000, sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA), 
then followed by incubation with peroxidase-coupled secondary antibodies. A Supersignal kit 
(Pierce, Rockford, IL) was used to visualize the bands according to the manufacturer’s 
instructions. 
 
Statistical analysis 
The data obtained from at least three independent tests are presented as means±S.E.M 
and statistical comparisons between groups performed using 1-way ANOVA followed 
by Student’s t-test at P values of ＜0.001(***), ＜0.01(**) or＜0.05(*). 
 
Results 
Effect of CTs on B16 and B16BL6 melanoma cell growth 
The aim of this study was to investigate the possible roles of CTs on melanoma cell 
lines with different metastatic capacity. First of all, we established an in vivo 
experimental metastasis model to confirm the exact metastatic capacity of B16 
(low-metastatic potential) and B16BL6 (high-metastatic potential) melanoma cell lines. 
Compared with the B16 melanoma cell group, B16BL6 melanoma cells increased 
remarkably the lung weight and the number of tumor nodules on the lung surface in the 
experimental metastasis model (Supplementary Fig. 1).  
We then assessed the effect of CTs on cell growth of B16 and B16BL6 melanoma cell 
lines in vitro. Exponentially growing cells were cultured with different concentrations 
of CTs for 24 h, and then cell growth evaluated by the MTT assay. As shown in Fig. 1A, 
CTs caused a strong concentration-dependent inhibition in B16 and B16BL6 melanoma 
cell growth. IC50 values of CTs on B16 and B16BL6 cells were 12.37 μM and 8.65 μM, 
respectively. Cells were then treated with various concentrations of CTs (0, 1, 10, and 
25 μM) for different periods of time (4, 8, 12, 16, 20 and 24 h) and the MTT assay 
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performed at the end of each treatment. A marked reduction in viable cell count was 
observed after treatment with CTs in both a time- and dose-dependent manner (Fig. 1B). 
At the same time, the cell viability following CTs treatment was further confirmed by 
morphological analyses. The present results demonstrated that CTs was able to inhibit 
cell growth and induce morphological changes (Fig. 1C). The cytotoxic effect of CTs on 
B16 and B16BL6 cells was also determined using the LDH assay (Fig. 1D). We found 
that cytotoxic effects triggered by CTs occurred at concentrations above 25 μM, with 
significant effects seen at 50-100 μM, and that there was no significant adverse effect of 
CTs at lower (0-25 μM) concentrations. These results indicated that the growth 
inhibition of CTs (0-25 μM) was due to cytostatic rather than cytotoxic effects. 
 
Effect of CTs on B16 and B16BL6 melanoma cell apoptosis 
To determine whether the growth inhibitory effect of CTs was associated with the 
induction of apoptosis, B16 and B16BL6 cells were exposed to CTs (0, 1, 10, and 25 
μM) for 24 h. After that, these cells were stained with annexin-V FITC & propidium 
iodide (PI) and then determined by flow cytometry. As shown in Fig. 2A, CTs increased 
the percentage of apoptotic cells in a concentration-dependent manner, but the effect 
was slight. At 25 μM, CTs only induced apoptosis in approximately 4% of Cells.  
Similar results were obtained in B16BL6 cells, suggesting that the effect of CTs on the 
induction of apoptosis in both B16 and B16BL6 melanoma cells was of lesser relevance. 
FITC-linked Annexin V/propidium iodide staining assay provides a simple and 
effective method to detect apoptosis at a very early stage, while terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) is a method for 
identifying cells in the last phase of apoptosis. To further strengthen the evidence, 
TUNEL assay was used to confirm the effect of CTs on apoptosis, and confirmatory 
results were obtained by TUNEL staining through counting the apoptotic cells (Fig. 
2B).  
 
Effect of CTs on B16 and B16BL6 melanoma cell proliferation (DNA Synthesis) 
Cell proliferation and apoptosis are intimately linked, thus the coordination, and balance, 
between these two processes is crucial for normal cell physiology. Although CTs 
decreased the number of B16 and B16BL6 melanoma cells there was no obvious 
apoptosis as measured by AnexinV and TUNEL assays. The growth of cells in the 
presence of BrdU, which is incorporated into newly synthesized DNA of actively 
proliferating cells, has become an accepted method for monitoring DNA replication [21, 
22]. When the cell enters the S phase (DNA Synthesis) the cellular DNA is duplicated, 
to ensure each daughter cell will receive a complete set of genetic information. To 
determine the effect of CTs on cell proliferation in the S phase, BrdU incorporation was 
used to define the kinetics of DNA synthesis after CTs treatment. Cells in S phase were 
labeled by BrdU incorporation, assayed by immunostaining and counted using Confocal 
microscopy. CTs treatment resulted in a decreased number of BrdU-positive cells in a 
dose-dependent manner (Fig. 3), indicating that the percentage of cells in the S phase, 
and hence undergoing DNA synthesis, was reduced. 
 
Effect of CTs on B16 and B16BL6 melanoma cell cycle 
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The cell cycle is a critical regulator of the processes involved in cell proliferation and 
growth, as well as cell division after DNA damage. To explore whether the observed 
growth inhibitory effect of CTs was caused by specifically perturbing cell cycle-related 
events, a set of experiments were performed to measure both DNA content and the cell 
cycle distribution of CTs-treated, or untreated, cells by flow cytometry after staining 
with PI. As shown in Fig. 4, the population of cells in the S phase continuously 
decreased both in B16 and B16BL6 cells in a concentration- and time-dependent 
manner after exposure to CTs, consistent with the results of the BrdU assay. At the 
same time, the sub-G1 peak (apoptosis peak) was not observable, which was consistent 
with the results of Anexin V and TUNEL assay. Interestingly, the data indicated that 
during the 48 h time period, treatment of B16 and B16BL6 cells with CTs led to a 
marked accumulation of cells in the G2 phase and G1 phase respectively. This effect 
was both concentration- and time-dependent, suggesting that the growth inhibition was 
the result of a block during the G1 phase, and that such cells do not enter the S phase. 
Alternatively, it may suggest that it arises from a block during the G2 phase, and that 
such cells do not enter the M phase. Such effects were not observed in control cells. The 
CTs-treated cells (25 μM) showed the typical patterns of DNA content that arrested at 
G2/M phase in B16 cells (Fig. 4B a) and blocked at G1 phase in B16BL6 cells (Fig. 4B 
b), respectively.  
 
Mutational Analyses of B-RAF and N-RAS in B16 and B16BL6 cell lines 
Defects in DNA damage responses may underlie genetic instability and malignant 
progression in melanoma. Normal human melanocytes (NHMs) display effective G1 
and G2 checkpoint responses to ionizing radiation-induced DNA damage. A majority of 
melanoma cell lines (11/16) display significant quantitative defects in one or both 
checkpoints. For example, melanomas with B-RAF mutations as a class display a 
significant defect in DNA damage G2 checkpoints. In contrast, the epithelial-like 
subtype of melanomas with wild-type N-RAS and B-RAF alleles display an effective 
G2 checkpoint, but a significant defect in G1 checkpoint function [5]. In the current 
experiments, flow cytometry indicated that CTs induced G1 arrest in B16BL6 and G2 
arrest in B16. The question was, why did CTs have opposite effects on cell cycle events 
in these two cell lines? We hypothesized that high-metastatic (B16BL6) and 
low-metastatic (B16) potential melanoma cell lines could display different defects in 
cell cycle checkpoint functions, in order for cells to proliferate with the chromosomal 
instability that characterizes this malignancy. We thus analyzed genomic DNA from 
B16 and B16BL6 melanoma cell lines for oncogenic mutations in N-RAS and B-RAF. 
However, sequencing of the PCR products did not reveal any mutations in these two 
cell lines (data not shown). 
 
Effect of CTs on the expression of cell cycle associated proteins in B16 and B16BL6 
melanoma cells 
Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the 
order and fidelity of cell cycle events. These checkpoints verify whether the processes at 
each phase of the cell cycle have been accurately completed before progression into the 
next phase. When defects in the division program of a cell are detected, checkpoints 
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prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk 
complexes [23]. Cell cycle progression is regulated by checkpoint controls that function 
to protect the integrity of the genome. Such controls act to prevent cell cycle 
progression until after completion of prior events [24]. The G1 checkpoint permits 
repair prior to replication, whereas arrest at the G2 checkpoint permits repair of the 
genome prior to its mitotic segregation. G1 arrest is controlled primarily by the tumor 
suppressor p53, which is activated in response to various forms of stress, that binds to 
the promoters of target genes and induces their transcription [25]. Chk 1 and Chk 2 both 
function as essential components in the G2 DNA damage checkpoint by 
phosphorylating Cdc25c in response to DNA damage [26]. We speculated that the 
different cell cycle events induced by CTs in B16 and B16BL6 cells was correlated with 
the induction of different checkpoint associated proteins. We thus performed western 
blotting analysis to assess the levels of cell cycle checkpoint regulators of p53, Chk1 
and Chk2. The expression of p53, Chk1 and Chk2 were both increased in B16 and 
B16BL6 cells at 24 h following treatment with CTs (Fig.5A), though the degree of the 
increase and the basal expression of p53, Chk1 and Chk2 was slightly different in B16 
as compared to B16BL6 cells. 
To further understand the molecular mechanisms involved, we next investigated the 
effects of CTs on the cyclin-dependent kinase (Cdk) inhibitor, p21 [27], which mediates 
p53-dependent G1 growth arrest. Incubation of B16BL6 cells with CTs, which arrested 
at G1 phase, caused a dose-dependent increase in p21 protein level. On the other hand, 
CTs treatment of B16 cells, which led to a cell cycle arrest at G2 phase in these cells, 
induced only a slight increase in the level of p21 (Fig.5B). In addition, a major and 
crucial target for Chk1 and Chk2 in cell cycle checkpoints is the dual-specificity 
phosphatase Cdc25, which dephosphorylates and activates Cdks [28, 29]. We found that 
the level of Cdc25c was increased in B16, but decreased in B16BL6, cells in response to 
CTs treatment (Fig.5B). 
In mammalian cells, progression through the G2 phase of the cell cycle is mediated by a 
specific set of proteins, which includes Cyclins A1, B1, mitotic kinase cdk1 (alias 
p34Cdc2) [30]. Western blotting analysis of cell samples obtained after CTs treatment 
for 24 h showed significant changes in the intracellular protein levels of Cyclin A1, 
Cyclin B1 and Cdc2 as compared with the untreated control (Fig.5C). After CTs 
treatment B16 cells in the G2/M phase expressed Cyclin A1,Cyclin B1 and Cdk1/cdc2 
at a higher level, while B16BL6 cells in the G1 phase expressed these regulatory 
proteins at a lower level. Our present study established that CTs induced G1 arrest in 
B16BL6 cells, together with an increase in p21 protein level. However, CTs blocked 
B16 cells in G2 phase, along with an accumulation of Cdc25c, Cyclin A1,Cyclin B1 and 
Cdk1/cdc2 protein level. 
 
Discussion 
Melanoma is the second most rapidly growing type of cancer in humans [31]. It is 
characterized by a high metastatic propensity, resistance to any known cancer therapies, 
and extremely poor patient survival rate. In this study, the results showed that CTs was a 
potent inhibitor of B16 and B16BL6 melanoma cell growth. The balance of cell 
progression is a series of tightly integrated events which allows cells to grow, 
10 
 
proliferate and die. However, we could not detect any obvious apoptosis in CTs-treated 
cells. Subsequent experiments addressed whether CTs inhibited cell proliferation, as 
measured by the BrdU assay. The data for CTs-treated cells clearly revealed a 
significant reduction in cells in the S phase. To confirm that the effect induced by CTs 
was associated with the arrest of cells in a particular phase, we analyzed cell distribution 
at each phase of the cell cycle by flow cytometry. We found that CTs inhibited the cell 
proliferation by inducing the G2/M arrest in a dose-dependent manner in the B16 cell 
line. This observation was different from the results obtained from the B16BL6 cell line, 
which showed an increased cell population in the G1 phase.  
 
We hypothesized that CTs induced G1 arrest in B16BL6 cell line (high-metastatic 
potential) and G2 arrest in B16 cell line (low-metastatic potential), and that this 
depended on the integrity of different checkpoint controls in these different cell lines, or 
the different cell cycle regulators induced by CTs. As defects in cell cycle checkpoint 
function are comparatively common in melanoma cell lines [5], we tested this 
hypothesis, by investigating whether the two cell lines displayed different defects in cell 
cycle checkpoint controls by mutational analyses of B-RAF and N-RAS genes. 
However, sequencing of the PCR products did not reveal any mutations.  
 
We then examined the expression of intracellular proteins involved in regulating the cell 
cycle at the G1 or G2/M boundary. There are well-known CDK inhibitors, such as 
p16NK4a, p21WAF1/CIP1, and p27KIP1, which bind to and inhibit the CDK-cyclin complexes 
[32]. It has been reported that p53 regulates a DNA damage-triggered G1 checkpoint by 
up-regulation of p21WAF1/CIP1 [33]. p21WAF1/CIP1 is not only activated by the p53 protein, 
but it also blocks the cell cycle at the G1 phase [34]. The cell cycle G2/M checkpoint 
control appears to involve a number of proteins in a wide variety of eukaryotic cells., 
such as: Cyclin A; Cyclin B; Cdk1/cdc2; Cdc25; Chk1 and Chk2, as well as DNA 
damage sensor proteins. To explore the molecular mechanisms of CTs-induced cell 
cycle arrest, we analyzed the levels of these cell cycle regulatory proteins in B16 and 
B16BL6 cell lines. We demonstrated that CTs induced the expression of p53, Chk1 and 
Chk2 in both B16 and B16BL6. Interestingly, CTs induced G1 arrest in B16BL6 cells, 
together with an increase in p21 protein level. By contrast, in B16 cells, CTs induced 
the G2/M arrest through induction of Cdc25c. Furthermore, regulation of the levels of 
expression of Cyclin A1, Cyclin B1 and Cdk1/cdc2 might also contribute to the 
different cell cycle patterns in B16 and B16BL6 cells following CTs treatment. It has 
been shown that the expression of cell cycle regulatory proteins was activated by CTs, 
suggesting that CTs-induced G2 arrest in B16 cell line might be mediated via the 
signaling cascade, involving a distinct cascade of check-point kinases (Chk → Cdc25C 
→ G2 phase). On the other hand, p53 might regulate a DNA damage-triggered G1 
checkpoint by up-regulation of p21WAF1/CIP1 in CTs-induced B16BL6 cells (p53 → p21 
→ G1 phase). Thus, we supposed that such phenomenon was correlated to DNA 
damage and different cell cycle-regulatory proteins status induced by CTs in different 
metastatic potential melanoma cell lines. These results suggested that modulation of cell 
cycle-regulatory proteins might be a possible molecular mechanism of the action of 
CTs. 
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CTs was shown to arrest B16BL6 cells in G1 and block B16 cells at the G2/M transition. 
The reason for this difference in behavior induced by CTs in these two cell lines might 
be due to their distinct properties of these two cell lines. Similar conflicting results have 
been presented in other reports. For example, quercetin has been shown to block the cell 
cycle at the G1/S transition in colon and gastric cancer cells as well as in leukemic cells. 
By contrast, it has been found to cause a G2/M block in breast and laryngeal cancer cell 
lines, and in non-oncogenic fibroblasts [35]. Similarly, reports have indicated that 
As2O3 treatment resulted in cell-cycle arrest at either G1 or G2/M phase depending on 
the cell line used [36].  
 
The results also revealed differences in structure-activity relationship between the 
tanshinones. Mosaddik [37] has studied the cytotoxic effect of four tanshinones isolated 
from the dried root of Salvia miltiorrhiza Bunge on P388 lymphocytic leukemia cells, 
and suggested that the unsaturation at C-15 and saturation on ring A may be critical 
structural components for the cytotoxicity of these diterpenes. This result was consistent 
with our study in that cryptotanshinone, which lacks saturation at C-15, showed little 
cytotoxicity, but possessed a potent cytostatic effect. Therefore, due to this lack of 
cytoxic effects, CTs may have potential as a lead compound in the development of 
chemotherapeutic agents. While the anti-proliferative effect of CTs represent a potential 
cancer chemopreventive mechanism, the cell cycle effect of CTs in vivo also requires 
further study. Furthermore, CTs, which appears to have opposite effects on cell cycle 
events in melanoma cell lines with different metastatic capacity, offers a useful tool to 
investigate the reasons behind such different patterns of malignancy. 
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Figures and Figure legends 
 
Fig.1. Effect of CTs on B16 and B16BL6 melanoma cell growth. (A) The effect of CTs in different 
concentrations on B16 and B16BL6 melanoma cell growth. (B) The effect of CTs on B16 and 
B16BL6 melanoma cell growth at different time points. The cell growth was evaluated by MTT 
assay. The reading of control was normalized to 100%, and readings from CTs-treated cells were 
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expressed as % of control (CTs 0 μM). (C) The effect of CTs on B16 and B16BL6 melanoma cell 
morphology. After incubation with CTs for 24 h, images of the cell morphological changes were 
taken with an inverted microscope at a ×100 magnification. (D) The cytotoxic effect of CTs on B16 
and B16BL6 melanoma cell. After treatment with CTs for 24 h, culture supernatants were then 
collected and cell cytotoxicity was measured by LDH release assay. Values are presented as fold 
normalized activity relative to that of control. Data are all presented as mean±s.e.m (*= P <0.05, 
**= P< 0.01, ***= P< 0.001 versus control). (a) for B16 melanoma cell line; (b) for B16BL6 
melanoma cell line. 
 
 
Fig.2. Effect of CTs on B16 and B16BL6 melanoma cell apoptosis. (A) The effect of CTs on B16 
and B16BL6 melanoma cell apoptosis in the early stage. (B) The effect of CTs on B16 and B16BL6 
melanoma cell apoptosis in the last phase. Proliferating cells were exposed to CTs (0, 1, 10, and 25 
μM) for 24 h, and the apoptotic cells in the early stage were determined by Annexin V/PI using flow 
cytometric analysis. The Annexin V labelling index was defined as the percentage of Annexin V 
positive and PI negative cells against total cells counted.  The apoptotic cells in the last phase were 
measured by TUNEL immunofluorescence assay, then visualized and photographed using Leica 
TCS-SL confocal system. At least 5 randomly chosen areas in every slide were taken. The TUNEL 
labelling index was defined as the percentage of TUNEL positive cells against total cells counted. 
Columns, mean of triplicates; bars, ±s.e.m (*= P <0.05 versus control). (a) for B16 melanoma cell 
line; (b) for B16BL6 melanoma cell line. 
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Fig.3. Effect of CTs on B16 and B16BL6 melanoma cell proliferation (DNA Synthesis). Cells were 
seeded on Poly-L-Lysine coated cover glass slides in 6-well plates, and treated with CTs (0, 1, 10, 
25μM) for 24 h. After that, cells were incubated with BrdU at a final concentration of 10 μM for 30 
minutes. Cells in S phase (DNA Synthesis) were labelled by BrdU incorporation, assayed by 
immunostaining and counted by confocal microscope. The representative photographs of 
immunofluorescence of BrdU (green) and Topro-3 (red) in CTs treated cells were shown in (A). At 
least 5 randomly chosen areas in every slide were taken. The BrdU labelling index was shown in (B), 
which defined as the percentage of BrdU positive cells (green) against total cells (red) counted. 
Columns, mean of triplicates; bars, ±s.e.m (**= P <0.01, ***= P <0.001 versus control). (a) for B16 
melanoma cell line; (b) for B16BL6 melanoma cell line. 
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Fig.4. Effect of CTs on B16 and B16BL6 melanoma cell cycle. Cells were plated at 3x105 cells per 
60-mm dish, incubated for 12 h, transfered to fresh medium and treated with different concentrations 
of CTs (0, 1, 10, 25 μM) for 0, 6, 12, 24,48 h. After incubation for different periods of time, cells 
were collected, stained and analyzed by flow cytometry for cell distribution at each phase of the cell 
cycle. (A) Calculation of cell cycle distribution using CellQuest analysis software. Data are the 
means ±s.e.m obtained from a triplicate of each experiment. *= P <0.1, **= P <0.01, ***= P <0.001 
versus control (CTs 0 μM, 0 h). (B) The typical pattern of DNA content of cell cycle distribution in 
CTs (25 μM) treated cells at different time points. (a) for B16 melanoma cell line; (b) for B16BL6 
melanoma cell line. 
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Fig.5. Effect of CTs on the expression of cell cycle associated proteins in B16 and B16BL6 
melanoma cells. Cells were treated with CTs (0, 1, 10, 25 μM) for 24 h. Whole cell extracts were 
analyzed by western blotting using the indicated antibody. β-actin or GAPDH was used as an 
internal control to monitor equal protein loading. (A) The effect of CTs on the expression of p53, 
Chk1 and Chk2 in B16 and B16BL6 melanoma cells. (B) The effect of CTs on the expression of p21 
and Cdc25c in B16 and B16BL6 melanoma cells. (C) The effect of CTs on the expression of Cyclin 
A1, Cyclin B1 and Cdk1/cdc2 in B16 and B16BL6 melanoma cells. 
 
 
Supplementary Fig.1. Comparison of metastatic behavior between B16 and B16BL6 melanoma cells. 
In a model of experimental metastasis, mice were sacrificed at 23 days after tumor cells injection. The 
lungs were removed, washed with PBS, and fixed in 10% v/v formaldehyde. The metastatic colonies 
were counted under a dissecting microscope. (A) The lungs were photographed to show the capacity of 
metastasis between B16 and B16BL6 melanoma cells. (B) The lung weight of B16 and B16BL6 group 
in experimental metastasis model. (C) The number of lung metastasis foci in each group. Columns, mean: 
B16 group (n=6), B16BL6 group (n=5); bars, ±s.e.m., ** = P< 0.01 versus B16 group. 
 
 
